Hearing the call of its investors, Unilever PLC has “drawn a line under the GSK Consumer Health proposal” and does not intend to pursue other major acquisitions in the foreseeable future, CEO & Executive Director Alan Jope told analysts during a 10 February year-end earnings presentation.
Unilever Vows No GSK-Sized Ventures For Foreseeable Future, Commits To Existing Brands In 2022
Opening the company’s fiscal 2021 full-year earnings call, Unilever leadership assured investors it will not make any GSK-sized offers in the foreseeable future as it commits to organic growth and reshaping its portfolio more surgically through bolt-on deals and selective disposals.

More from Business
Arkopharma's parent company Dermapharm is undertaking a strategic shift at the French firm to help it better compete in the dietary supplements market after a tough year.
Vitawell seeking to empower consumers left confused by the vast array of dietary supplements available to them in the UK.
Chinese consumers are now routinely taking supplements for a variety of health reasons, helping to drive up sales of the Swisse Plus+ brand by 20% in 2024.
Growing use of GLP-1 receptor agonists is having a positive knock-on effect on the dietary supplements market, reports OptiBiotix Health, marketer of the SlimBiome weight management prebiotic.
More from Wellness
“It's kind of a free for all,” says longtime FDA funding advocate Steven Grossman. FDA knew funding it requested “was totally inadequate to the needs. So, Food Chemical Safety is stuck there with about six or eight other purposes the money could have been used for.
Chinese consumers are now routinely taking supplements for a variety of health reasons, helping to drive up sales of the Swisse Plus+ brand by 20% in 2024.
FDA says “extension affords covered entities the additional time necessary to ensure complete coordination across the supply chain in order to fully implement the final rule’s requirements—ultimately providing FDA and consumers with greater transparency and food safety.”